Literature DB >> 29440927

Adrenal myelolipoma with hyperandrogenemia and schizophrenia.

Ningning Liu1,2, Wenhua Zhang3, Jiangshan Tan1,4, Jiaxin Zhou1, Xiaopeng Yu5, Ningxin Ren5, Zhiqing Fang3, Wei Jiao3, Yidong Fan3, Cheng Liu6.   

Abstract

Adrenal myelolipoma with hyperandrogenemia is extremely rare. We report a case of a 26-year-old Chinese female with schizophrenia, who presented with a hormonally active tumor causing hyperandrogenemia. The mass was found by computerized tomography when she had her gynecologic examination for secondary amenorrhea, and it was confirmed to be an adrenal myelolipoma after a histopathological study. She was referred for a left adrenal laparoscopic excision, and the size of adrenal myelolipoma was found to be more than 10 cm. We report this case because large adrenal myelolipomas with hyperandrogenemia and schizophrenia are rare, and adrenal myelolipoma associated with hyperandrogenemia might be determined by the enzymes involved in the production of hormones.

Entities:  

Keywords:  adrenal; hyperandrogenemia; myelolipoma; schizophrenia

Year:  2018        PMID: 29440927      PMCID: PMC5798574          DOI: 10.2147/CMAR.S145332

Source DB:  PubMed          Journal:  Cancer Manag Res        ISSN: 1179-1322            Impact factor:   3.989


Introduction

Adrenal myelolipoma is infrequently encountered nonfunctioning benign tumor of unknown etiology. In some cases, it presents endocrine disorders, such as Cushing’s syndrome, Conn’s syndrome, and congenital adrenal hyperplasia.1 But few cases of virilization have been reported. To our knowledge, this kind of case is very rare, and there are only three related documented case reports in the English literature. Except for virilization and other common symptoms, this kind of adrenal myelolipoma often accompanies other abnormalities such as type-2 diabetes mellitus, acanthosis nigricans, and growth retardation. We report one case with schizophrenia, and we hypothesize that it is associated with her tumor.

Case report

A 26-year-old woman with schizophrenia was admitted to our hospital for a left adrenal mass found when she had her gynecologic examination for secondary amenorrhea. The patient was a hepatitis B positive female with a history of schizophrenia for more than 10 years, who exhibited male characteristics (including hirsutism and menoxenia) but with no lumbago. At the age of 13 years, the patient began to menstruate, but the cycles were rather irregular. Six years ago, her menstruation cycle became normal because she was consuming ethinylestradiol and cyproterone acetate tablets. In addition, she has been taking antipsychotic drugs for more than 10 years. On a through laboratory examination, the patient had a high level of plasma testosterone (328.79 ng/mL). Complete blood count revealed increasing leukocytes (47.00/µL), thrombocytocrit (0.41%), and epithelia (33.5/µL). The level of plasma cortisol aldosterone, basal plasma renin activity, and angiotensin II showed no obvious abnormality. Abdominal sonography showed that there was a well-defined hyperechoic heterogeneous mass of 11.0×10.1×10.1 between the left adrenal gland and spleen. Computerized tomography scan of the abdomen with oral and intravenous contrast showed a big nonhomogeneous mass pushing the left kidney down in the left upper quadrant. It measured approximately 11.6×10.0 cm with multiple septa which showed slight enhancement in arterial phase and moderate enhancement in venous phase, so did the solid component of the tumor. This mass also had a vaguely defined border with the tail of the pancreas and spleen. Besides, a low-density lesion could be seen in the left lobe of the liver (Figures 1 and 2).
Figure 1

Coronal image from contrast-enhanced CT showing a left adrenal mass; left kidney is displaced inferiorly by the mass.

Abbreviation: CT, computerized tomography.

Figure 2

Axial plane showing adipose tissue and septations.

Notes: Tiny foci of calcifications are also visible in the lateral wall of the mass.

The left adrenal mass specimen measured 13.5×10.5×6.5 cm. A mixture of mature adipose tissue and bone marrow elements could be seen in the low-power histological picture (Figure 3). Immunohistochemical staining was performed for Syn, Ck, Hmb45, Melan-A, Hmb45, and cgA (Figure 3).
Figure 3

Low-power histological image showing a mixture of mature adipose tissue and bone marrow elements (×10).

The patient was referred for a left adrenal laparoscopic excision, and the postoperative hospital course was uneventful. She recovered quickly, and the level of plasma testosterone was 0.68 ng/mL (Figure 4). Her menstruation soon became regular and endocrine examinations returned to normal.
Figure 4

The patient was referred for a left adrenal laparoscopic excision on August 22, 2016.

Notes: After the surgery, her plasma testosterone level was back to normal.

The patient’s family gave their written informed consent for all or any part of this material to appear in this paper and all editions of Cancer Management and Research, and any other works or products, in any form or medium.

Discussion

Myelolipoma is a rare and benign neoplasm which was first described by Gierkein2 and named by Oberling in 1929. In the previously reported cases, endocrine disorders, such as Cushing’s syndrome, Conn’s syndrome, and congenital adrenal hyperplasia as a result of 17a-hydroxylase or 21a-hydroxylase deficiency,1 were found to be associated with functioning tumors, myelolipoma with virilization was very rare, especially with such a large mass. Most myelolipomas are asymptomatic and discovered incidentally on abdominal imaging, such as ultrasonography and computerized tomography, for some other indications.1 Some may present with abdominal pain because of huge size or hemorrhage or necrosis within tumor. The patient in the current case had no abdominal pain or other related discomfort even though the size of adrenal myelolipoma was more than 10 cm. That was why she did not find that her virilization was associated with the adrenal tumor until she underwent a gynecologic examination for secondary amenorrhea. The etiology of adrenal myelolipoma is still unknown. Past researches found adrenal myelolipoma is associated with long periods of elevated ACTH. In addition, chronic stressful conditions such as diabetes mellitus, hypertension, obesity, chronic inflammatory processes, and malignancy are also be observed in patients with adrenal myelolipoma.3 On examination, the body mass index of the patient in the current case was 27.89 kg/m2, which is indicative of obesity. But, she has neither hypertension nor diabetes. Adrenal myelolipoma associated with hyperandrogenemia is much rarer (Table 1). One report hypothesizes that it might be determined by the aforementioned multiple factors, extrinsic compression of the large tumor, and the enzymes involved in the production of hormones, such as melamin-A,4 In our case, Melan-A immunohistochemical staining was also positive. In addition, positive Syn staining indicated that the mass had neuroendocrine function, which could explain the elevated levels of androgen. In addition, extra-adrenal myelolipoma with virilization and Cushing’s syndrome has also been reported before in patients whose immunohistochemistry showed that the mass was positive for calretinin, Melan-A, and Syn.5
Table 1

Adrenal myelolipoma associated with hyperandrogenemia

StudySizeAge (years)Left/rightCortisolLumbar region
Moskovitz et al,10 19893.5×3×234Right//
Tasnim Ahsan et al,11 20105.5×4.525Left/Yes
Su et al,4 20127×534RightNormalYes
Our case13.5×10×6.526LeftNormalNo

Note: “/” indicates that the study gave no information about this factor.

This patient had a history of schizophrenia for more than 9 years and has been taking antipsychotic drugs for more than 5 years. Schizophrenia is a brain disorder that affects how people think, feel, and perceive. People with schizophrenia can experience both hyper- and hypofunction of the hypothalamic–pituitary–adrenal axis,6 as shown by a new study. In addition, another study shows that patients with schizotypal disorder, compared with healthy control subjects, have an enlarged pituitary volume.7 So, we hypothesize that her schizophrenia may have caused the adrenal myelolipoma. Or, her schizophrenia may have been caused by the adrenal myelolipoma. People hold different opinion regarding the size criteria for adrenal myelolipomas as an indication for surgical resection. Previously, laparoscopic approach was not considered a good choice when the adrenal tumor size exceeded 5–6 cm. But through the recent advancement of diagnostic imaging methods, some surgeons demonstrated that laparoscopic adrenalectomy could be used in giant adrenal myelolipoma.8 A tumor with a large size, 15 cm at its longest dimension, has been resected by the laparoscopic approach recently.9 The tumor mass in our patient was removed with laparoscopic resection, and her postoperative hospital course was uneventful. Adrenal myelolipoma with virilization is very rare. We reported here a case with schizophrenia, and we hypothesize that this may explain the pathogenesis of the present case, or, vice versa, the adrenal myelolipoma could have caused her schizophrenia. In addition, this case supports the hypothesis that adrenal myelolipoma associated with hyperandrogenemia might be determined by the enzymes involved in the production of hormones.

Limitations

Disadvantage: It is only our conjecture that her schizophrenia is related to this tumor. Long-term follow-up should been done to observe the mental disorder and adrenal gland varieties of these patients by using imaging methods. If it is possible, genetic tests are likely to be helpful too.
  10 in total

Review 1.  A systematic review of hypothalamic-pituitary-adrenal axis function in schizophrenia: implications for mortality.

Authors:  Andrew J Bradley; Timothy G Dinan
Journal:  J Psychopharmacol       Date:  2010-11       Impact factor: 4.153

2.  An Unusual Cause of Cushing's Syndrome and Virilization.

Authors:  Wei Liu; Weijie Chen; Xiaodong He
Journal:  Gastroenterology       Date:  2015-08-21       Impact factor: 22.682

3.  Laparoscopic hand-assisted adrenal sparing surgery for a giant adrenal myelolipoma: A case report.

Authors:  Bong Hee Park; Su Lim Lee; Kyung Jin Seo; Sang Rak Bae; Yong Seok Lee; Sung Hak Kang; Chang Hee Han
Journal:  Int Surg       Date:  2015-05-19

4.  Virilization with adrenal myelolipoma, adrenal hyperplasia, and fibroadenoma of breast.

Authors:  Tasnim Ahsan; Subheen Kanwal; Zeenat Banu; Rukhshanda Jabeen
Journal:  J Coll Physicians Surg Pak       Date:  2010-12       Impact factor: 0.711

5.  Is size really a contraindication for laparoscopic resection of giant adrenal myelolipomas?

Authors:  Ranjit Chaudhary; Abhijeet Deshmukh; Kulwant Singh; Rakesh Biswas
Journal:  BMJ Case Rep       Date:  2016-03-17

6.  Adrenal myelolipoma associated with hyperandrogenemia.

Authors:  Heng-Chuan Su; Xin Huang; Jun Dai; Fu-Kang Sun
Journal:  Int J Urol       Date:  2012-07-13       Impact factor: 3.369

7.  Adrenal myelolipoma.

Authors:  W F Gee; P M Chikos; J P Greaves; N IKEMOTO; J A Tremann
Journal:  Urology       Date:  1975-04       Impact factor: 2.649

8.  Adrenal myelolipoma simulating virilizing adrenal tumor.

Authors:  B Moskovitz; M Bolkier; Y Katz; Y Ben Arieh; D Richter Levin
Journal:  Urol Int       Date:  1989       Impact factor: 2.089

9.  Combined adrenal adenoma and myelolipoma in a patient with Cushing's syndrome: case report and review of the literature.

Authors:  Hiroshi Hisamatsu; Hideki Sakai; Satoshi Tsuda; Kazuto Shigematsu; Hiroshi Kanetake
Journal:  Int J Urol       Date:  2004-06       Impact factor: 3.369

10.  Increased pituitary volume in schizophrenia spectrum disorders.

Authors:  Tsutomu Takahashi; Michio Suzuki; Dennis Velakoulis; Valentina Lorenzetti; Bridget Soulsby; Shi-Yu Zhou; Kazue Nakamura; Hikaru Seto; Masayoshi Kurachi; Christos Pantelis
Journal:  Schizophr Res       Date:  2009-01-21       Impact factor: 4.939

  10 in total
  1 in total

1.  Adrenal myelolipoma: from tumorigenesis to management.

Authors:  Wassim Alaoui Mhammedi; Hicham Ouslim; Abdelghani Ouraghi; Mohammed Irzi; Amine Elhoumaidi; Amine Elhoumaidi; Mehdi Chennoufi; Mohammed Mokhtari; Anouar Elmouden; Ali Barki
Journal:  Pan Afr Med J       Date:  2019-12-05
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.